SZSE:300573 (China)
Â
Class A
Â¥
77.27
-1.73 (-2.19%)
Mar 28
What is a stock summary page? Click here for an overview.
Business Description
Shenyang Xingqi Pharmaceutical Co Ltd
ISIN : CNE100002DV1
Share Class Description:
SZSE:300573: Class ACompare
Compare
Traded in other countries / regions
300573.China Index Membership
SZSE Component IndexCHINEXT Price IndexCSI 500 Index IPO Date
2016-12-08Description
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company. It produces and sells opthalmic products. Its products include anti-bacterial products, corneal products, anti-inflammation products, anti-allergic, antifungal & among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.61 | |||||
| Interest Coverage | 91.02 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.34 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 25 | |||||
| 3-Year EBITDA Growth Rate | 28.4 | |||||
| 3-Year EPS without NRI Growth Rate | 37 | |||||
| 3-Year FCF Growth Rate | 53.6 | |||||
| 3-Year Book Growth Rate | 31.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 61.46 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 56.12 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.33 | |||||
| 9-Day RSI | 52.48 | |||||
| 14-Day RSI | 54.26 | |||||
| 3-1 Month Momentum % | -2.76 | |||||
| 6-1 Month Momentum % | -21.3 | |||||
| 12-1 Month Momentum % | -53.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | |||||
| Quick Ratio | 1.66 | |||||
| Cash Ratio | 1.04 | |||||
| Days Inventory | 129.11 | |||||
| Days Sales Outstanding | 40.43 | |||||
| Days Payable | 14.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.53 | |||||
| Dividend Payout Ratio | 1.46 | |||||
| 3-Year Dividend Growth Rate | 167.4 | |||||
| Forward Dividend Yield % | 1.29 | |||||
| 5-Year Yield-on-Cost % | 47.8 | |||||
| 3-Year Average Share Buyback Ratio | -2.6 | |||||
| Shareholder Yield % | 3.85 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.05 | |||||
| Operating Margin % | 23.68 | |||||
| Net Margin % | 19.34 | |||||
| FCF Margin % | 14.97 | |||||
| ROE % | 21.37 | |||||
| ROA % | 16.86 | |||||
| ROIC % | 26.42 | |||||
| 3-Year ROIIC % | 28.29 | |||||
| ROC (Joel Greenblatt) % | 40.48 | |||||
| ROCE % | 23.76 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.65 | |||||
| Forward PE Ratio | 17.85 | |||||
| PE Ratio without NRI | 37.58 | |||||
| Shiller PE Ratio | 93.1 | |||||
| Price-to-Owner-Earnings | 72.54 | |||||
| PEG Ratio | 0.78 | |||||
| PS Ratio | 7.46 | |||||
| PB Ratio | 8.32 | |||||
| Price-to-Tangible-Book | 9.49 | |||||
| Price-to-Free-Cash-Flow | 49.81 | |||||
| Price-to-Operating-Cash-Flow | 30.11 | |||||
| EV-to-EBIT | 33.56 | |||||
| EV-to-EBITDA | 33.56 | |||||
| EV-to-Revenue | 7.54 | |||||
| EV-to-FCF | 44.96 | |||||
| Price-to-GF-Value | 0.4 | |||||
| Price-to-Projected-FCF | 5.35 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.5 | |||||
| Price-to-Graham-Number | 3.98 | |||||
| Price-to-Net-Current-Asset-Value | 34.81 | |||||
| Earnings Yield (Greenblatt) % | 2.98 | |||||
| FCF Yield % | 1.99 | |||||
| Forward Rate of Return (Yacktman) % | 20.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenyang Xingqi Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,801.998 | ||
| EPS (TTM) (Â¥) | 1.999 | ||
| Beta | 1.39 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 77.36 | ||
| 14-Day RSI | 54.26 | ||
| 14-Day ATR (Â¥) | 3.233774 | ||
| 20-Day SMA (Â¥) | 74.289 | ||
| 12-1 Month Momentum % | -53.7 | ||
| 52-Week Range (Â¥) | 64.88 - 214.36 | ||
| Shares Outstanding (Mil) | 175.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenyang Xingqi Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenyang Xingqi Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenyang Xingqi Pharmaceutical Co Ltd Frequently Asked Questions
What is Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573)'s stock price today?
The current price of SZSE:300573 is ¥77.27. The 52 week high of SZSE:300573 is ¥214.36 and 52 week low is ¥64.88.
When is next earnings date of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573)?
The next earnings date of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is .
Does Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) pay dividends? If so, how much?
The Dividend Yield %  of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is 4.53% (As of Today), Highest Dividend Payout Ratio of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) was 1.94. The lowest was 0.12. And the median was 0.38. The  Forward Dividend Yield % of Shenyang Xingqi Pharmaceutical Co Ltd(SZSE:300573) is 1.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers